Marra C - Search Results

1

A quantitative benefit-risk analysis of isoniazid for treatment of latent tuberculosis infection using incremental benefit framework.

Sadatsafavi M, Marra C, Marra F, Moran O, FitzGerald JM, Lynd L. Sadatsafavi M, et al. Among authors: marra c, marra f. Value Health. 2013 Jan-Feb;16(1):66-75. doi: 10.1016/j.jval.2012.09.006. Value Health. 2013. PMID: 23337217 Free article.

2

Patient preference for latent tuberculosis infection preventive treatment: a discrete choice experiment.

Guo N, Marra CA, FitzGerald JM, Elwood RK, Anis AH, Marra F. Guo N, et al. Value Health. 2011 Sep-Oct;14(6):937-43. doi: 10.1016/j.jval.2011.05.003. Epub 2011 Jul 29. Value Health. 2011. PMID: 21914516 Free article.

3

Network vs. pairwise meta-analyses: a case study of the impact of an evidence-synthesis paradigm on value of information outcomes.

Zafari Z, Thorlund K, FitzGerald JM, Marra CA, Sadatsafavi M. Zafari Z, et al. Pharmacoeconomics. 2014 Oct;32(10):995-1004. doi: 10.1007/s40273-014-0179-1. Pharmacoeconomics. 2014. PMID: 24920194

4

Testing the External Validity of a Discrete Choice Experiment Method: An Application to Latent Tuberculosis Infection Treatment.

Mohammadi T, Bansback N, Marra F, Khakban A, Campbell JR, FitzGerald JM, Lynd LD, Marra CA. Mohammadi T, et al. Value Health. 2017 Jul-Aug;20(7):969-975. doi: 10.1016/j.jval.2017.04.007. Epub 2017 May 19. Value Health. 2017. PMID: 28712627 Free article.

5

Marra CA, Marra F, Colley L, Moadebi S, Elwood RK, Fitzgerald JM. Marra CA, et al. Chest. 2008 Feb;133(2):396-403. doi: 10.1378/chest.07-1494. Epub 2008 Jan 15. Chest. 2008. PMID: 18198260

6

Health state utilities in latent and active tuberculosis.

Guo N, Marra CA, Marra F, Moadebi S, Elwood RK, Fitzgerald JM. Guo N, et al. Value Health. 2008 Dec;11(7):1154-61. doi: 10.1111/j.1524-4733.2008.00355.x. Epub 2008 May 16. Value Health. 2008. PMID: 18489493 Free article.

7

Cost-effectiveness of LTBI treatment for TB contacts in British Columbia.

Tan MC, Marra CA, Sadatsafavi M, Marra F, Morán-Mendoza O, Moadebi S, Elwood RK, FitzGerald JM. Tan MC, et al. Among authors: marra ca, marra f. Value Health. 2008 Sep-Oct;11(5):842-52. doi: 10.1111/j.1524-4733.2008.00334.x. Epub 2008 Jul 15. Value Health. 2008. PMID: 18489519 Free article.

8

Measuring health-related quality of life in tuberculosis: a systematic review.

Guo N, Marra F, Marra CA. Guo N, et al. Health Qual Life Outcomes. 2009 Feb 18;7:14. doi: 10.1186/1477-7525-7-14. Health Qual Life Outcomes. 2009. PMID: 19224645 Free PMC article. Review.

9

A statistical method was used for the meta-analysis of tests for latent TB in the absence of a gold standard, combining random-effect and latent-class methods to estimate test accuracy.

Sadatsafavi M, Shahidi N, Marra F, FitzGerald MJ, Elwood KR, Guo N, Marra CA. Sadatsafavi M, et al. J Clin Epidemiol. 2010 Mar;63(3):257-69. doi: 10.1016/j.jclinepi.2009.04.008. Epub 2009 Aug 18. J Clin Epidemiol. 2010. PMID: 19692208 Review.

10

A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit framework.

Lynd LD, Marra CA, Najafzadeh M, Sadatsafavi M. Lynd LD, et al. Pharmacoepidemiol Drug Saf. 2010 Nov;19(11):1172-80. doi: 10.1002/pds.1994. Pharmacoepidemiol Drug Saf. 2010. PMID: 20602338

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

905 results

Search Page

Filters